{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzl4ke\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzl4ke\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/28\\\/17-a\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/28\\\/17-a\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/28\\\/17-a\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/28\\\/17-a\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003EA meta-analysis of 6 randomized trials demonstrated that when compared with aspirin therapy alone, dual antiplatelet therapy beyond 1 year decreased the risk of major adverse cardiovascular events, myocardial infarction, stroke, and cardiovascular death among high-risk patients with previous myocardial infarction while increasing the risk of major bleeding.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Cstrong\u003EDAPT\u003C\/strong\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Edual \u003Cstrong\u003Eantiplatelet therapy\u003C\/strong\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Cstrong\u003EMACE\u003C\/strong\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Emaj\u003Cstrong\u003Eor adverse cardiovascular event\u003C\/strong\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Cstrong\u003Emajor bleeding\u003C\/strong\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Cstrong\u003EMI\u003C\/strong\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Emyocardial infarction\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EA meta-analysis of randomized controlled trials has demonstrated a substantial reduction in cardiovascular (CV) outcomes, including CV mortality, with dual antiplatelet therapy (DAPT) continued beyond 1 year vs aspirin alone, among patients with a prior myocardial infarction (MI) [Udell JA et al. \u003Cem\u003EEur Heart J\u003C\/em\u003E. 2015].\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EThe recent trials examining the effect of extended DAPT in a variety of patient populations have produced heterogeneous results regarding its safety and efficacy, according to Jacob A. Udell, MD, MPH, University of Toronto, Toronto, Canada. He noted that in clinical practice DAPT is stopped at 1 year in about 50% of patients because of the lack of long-term data.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EDr Udell and colleagues conducted a systematic review and meta-analysis that evaluated whether long-term DAPT reduced CV risk when compared with aspirin alone in patients with a history of prior MI. The primary end point was a composite of major adverse CV events (MACEs) defined as CV death, MI, and stroke. The secondary end points included CV death, MI, stroke, non-CV death, all-cause mortality, major bleeding, and stent thrombosis.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EThe key features of the 6 trials included in the meta-analysis are shown in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E. The mean follow-up was 30 months, and there was a total of 2273 MACEs. The mean age of the patients was 64 years; 24% were women; and the mean time from MI was 18 months. Notably, few patients had unstable angina (7%), prior stroke or transient ischemic attack (3%), or prior coronary bypass surgery (7%).\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/16966\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/16966\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16966\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cp id=\u0022p-6\u0022 class=\u0022first-child\u0022\u003ETrials Evaluated in Meta-analysis\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-9\u0022\u003EThe results for the primary end point showed a significant risk reduction of 22% with prolonged DAPT, with low heterogeneity across the trials. The rate of MACEs was 6.4% among the 20\u2005203 patients assigned to DAPT vs 7.5% among the 13\u2005232 patients receiving aspirin alone (RR, 0.78; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.001; \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E). The rate of CV death alone was 2.3% for patients on DAPT vs 2.6% of those receiving aspirin (RR, 0.85; 95% CI, 0.74 to 0.98; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.03). Prolonged DAPT also significantly reduced the risk of individual CV end points, such as MI (RR, 0.70; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.003), stroke (RR, 0.81; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.02), and stent thrombosis (RR, 0.50; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.02).\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/28\/17.2\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Primary End Point: Major Adverse Cardiovascular EventRisk of major adverse cardiovascular events comparing extended dual antiplatelet therapy vs. aspirin alone. Square data markers represent risk ratios and horizontal lines the 95% confidence intervals with marker size reflecting the statistical weight of the study using inverse variance random effects meta-analysis. A diamond data marker represents the overall risk ratios and 95% confidence intervals for major adverse cardiovascular events. There was no significant between-trial heterogeneity (Q statistic\u0026#x2005;=\u0026#x2005;8.36, d.f. \u0026#x2005;=\u0026#x2005;5; P\u0026#x2005;=\u0026#x2005;0.14; I2\u0026#x2005;=\u0026#x2005;40%).CV, cardiovascular; DAPT, dual antiplatelet therapy; MI, myocardial infarction.Reprinted from Udell JA et al, Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials, Eur Heart J, 2015, by permission of Oxford University Press.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1305872865\u0022 data-figure-caption=\u0022\u0026amp;lt;div xmlns=\u0026amp;quot;http:\/\/www.w3.org\/1999\/xhtml\u0026amp;quot;\u0026amp;gt;Primary End Point: Major Adverse Cardiovascular EventRisk of major adverse cardiovascular events comparing extended dual antiplatelet therapy vs. aspirin alone. Square data markers represent risk ratios and horizontal lines the 95% confidence intervals with marker size reflecting the statistical weight of the study using inverse variance random effects meta-analysis. A diamond data marker represents the overall risk ratios and 95% confidence intervals for major adverse cardiovascular events. There was no significant between-trial heterogeneity (Q statistic\u0026#x2005;=\u0026#x2005;8.36, d.f. \u0026#x2005;=\u0026#x2005;5; \u0026amp;lt;em\u0026amp;gt;P\u0026amp;lt;\/em\u0026amp;gt;\u0026#x2005;=\u0026#x2005;0.14; \u0026amp;lt;em\u0026amp;gt;I\u0026amp;lt;\/em\u0026amp;gt;\u0026amp;lt;sup\u0026amp;gt;2\u0026amp;lt;\/sup\u0026amp;gt;\u0026#x2005;=\u0026#x2005;40%).CV, cardiovascular; DAPT, dual antiplatelet therapy; MI, myocardial infarction.Reprinted from Udell JA et al, Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials, \u0026amp;lt;em\u0026amp;gt;Eur Heart J\u0026amp;lt;\/em\u0026amp;gt;, 2015, by permission of Oxford University Press.\u0026amp;lt;\/div\u0026amp;gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/28\/17.2\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/28\/17.2\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/28\/17.2\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16965\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure1.\u003C\/span\u003E \u003Cp id=\u0022p-10\u0022 class=\u0022first-child\u0022\u003EPrimary End Point: Major Adverse Cardiovascular Event\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003ERisk of major adverse cardiovascular events comparing extended dual antiplatelet therapy vs. aspirin alone. Square data markers represent risk ratios and horizontal lines the 95% confidence intervals with marker size reflecting the statistical weight of the study using inverse variance random effects meta-analysis. A diamond data marker represents the overall risk ratios and 95% confidence intervals for major adverse cardiovascular events. There was no significant between-trial heterogeneity (Q statistic\u2005=\u20058.36, d.f. \u2005=\u20055; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u20050.14; \u003Cem\u003EI\u003C\/em\u003E\u003Csup\u003E2\u003C\/sup\u003E\u2005=\u200540%).\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003ECV, cardiovascular; DAPT, dual antiplatelet therapy; MI, myocardial infarction.\u003C\/p\u003E\u003Cp id=\u0022p-13\u0022\u003EReprinted from Udell JA et al, Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials, \u003Cem\u003EEur Heart J\u003C\/em\u003E, 2015, by permission of Oxford University Press.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-14\u0022\u003EThe rate of major bleeding was significantly higher among patients receiving DAPT vs aspirin alone, at 1.9% vs 1.1%, respectively (RR, 1.73; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.004). However, the rate of other bleeding events, such as intracranial hemorrhage (ICH), fatal bleeding, non-CV death, and all-cause death, was not significantly different between the treatment groups. All subgroup analyses demonstrated that extended DAPT was more effective than aspirin alone regardless of age, sex, DAPT regimen, index acute coronary syndrome, time from index MI, and history of percutaneous coronary intervention.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003EDr Udell concluded that extending DAPT beyond 1 year decreased the risk of MACE, MI, stroke, and CV death among high-risk patients with previous MI when compared with aspirin therapy alone. It also increased the risk of major bleeding but not fatal bleeding or ICH, and it did not increase the risk of death due to non-CV causes. However, he cautioned that prolonged DAPT is not appropriate for patients with anticoagulation issues, recent bleeding events or surgery, or history of ICH and that very few patients studied had prior stroke or a transient ischemic attack.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/28\/17.2.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzl4ke\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzl4ke\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzl4ke\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}